NASDAQ:ADIL Adial Pharmaceuticals Q2 2026 Earnings Report $4.20 +0.16 (+3.84%) As of 12:18 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Adial Pharmaceuticals EPS ResultsActual EPS-$11.25Consensus EPS -$1.03Beat/MissMissed by -$10.22One Year Ago EPSN/AAdial Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAdial Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/14/2026TimeAfter Market ClosesConference Call DateMonday, August 17, 2026Conference Call Time7:00AM ETUpcoming EarningsAdial Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Adial Pharmaceuticals Earnings HeadlinesAdial Pharmaceuticals, Inc. (NASDAQ:ADIL) Given Consensus Recommendation of "Hold" by AnalystsSeptember 23 at 4:15 AM | americanbankingnews.comAdial Pharmaceuticals (NASDAQ:ADIL) Trading Down 9.5% - Here's What HappenedSeptember 22 at 1:41 AM | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)Adial Pharmaceuticals Announces Board AppointmentsSeptember 18, 2026 | marketscreener.comMAdial Shareholders Approve Key Proposals, Meeting AdjournedSeptember 18, 2026 | tipranks.comAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)August 25, 2026 | globenewswire.comSee More Adial Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adial Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adial Pharmaceuticals and other key companies, straight to your email. Email Address About Adial PharmaceuticalsAdial Pharmaceuticals (NASDAQ:ADIL) is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders. The company’s primary focus is alcohol use disorder, a chronic condition characterized by problematic alcohol consumption and difficulty reducing or stopping use. Adial’s lead investigational product, AD04, is an oral, genetically targeted therapy based on ondansetron, a selective serotonin-3 receptor antagonist. The company is studying AD04 as a potential treatment for alcohol use disorder in patients identified through genetic or biomarker-based testing. This approach is intended to help target treatment to individuals who may be more likely to respond to the therapy. Based in Charlottesville, Virginia, Adial has also explored applications of its platform in other addictive disorders, including smoking cessation. The company’s programs remain in development and are subject to clinical, regulatory and commercial uncertainties. Cary Claiborne serves as the company’s president and chief executive officer.View Adial Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI Infrastructure Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
